Blockbuster Opportunity for Galena Biopharma? GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is unknown to most investors out there.  The company recently had news about the initiation of its Phase III PRESENT trial for NeuVax (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence.  Zacks Investment Research has a report on Galena showing a very favorable opinion.  If the possibilities here become reality, a $30 million market capitalization rate becomes the possibility for producing exponential returns to investors.  The downside is that the company is so small that if it suddenly failed it is too small for even the local newspaper in Lake Oswego, Oregon (Galena’s corporate HQ city) might not even report about it.

The NeuVax Phase III trial will be conducted in adjuvant breast cancer patient subsets, but Zacks noted that this initiation of the PRESENT Phase III trial of NeuVax is a major milestone which brings NeuVax a step closer to the market and to the breast cancer patients who need new treatment options.  The trial start is ahead of expectations and the market is broken down as follows:

• approximately 202,964 individuals are diagnosed with breast cancer each year in the U.S. alone
• about 10% or 20,000 of those patients are believed to be eligible for NeuVax treatment.
• NeuVax can reach a blockbuster status easily ($1 billion in annual sales).

Here is the link to access to the full report from Zacks.